DE602005010975D1 - Polymorphe formen eines gabaa-agonisten - Google Patents

Polymorphe formen eines gabaa-agonisten

Info

Publication number
DE602005010975D1
DE602005010975D1 DE602005010975T DE602005010975T DE602005010975D1 DE 602005010975 D1 DE602005010975 D1 DE 602005010975D1 DE 602005010975 T DE602005010975 T DE 602005010975T DE 602005010975 T DE602005010975 T DE 602005010975T DE 602005010975 D1 DE602005010975 D1 DE 602005010975D1
Authority
DE
Germany
Prior art keywords
polymorph
shapes
gabaa agonist
gabaa
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005010975T
Other languages
German (de)
English (en)
Inventor
Vincent Brett Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005010975(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of DE602005010975D1 publication Critical patent/DE602005010975D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005010975T 2004-01-30 2005-01-28 Polymorphe formen eines gabaa-agonisten Expired - Lifetime DE602005010975D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
PCT/GB2005/000288 WO2005073237A2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (1)

Publication Number Publication Date
DE602005010975D1 true DE602005010975D1 (de) 2008-12-24

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010975T Expired - Lifetime DE602005010975D1 (de) 2004-01-30 2005-01-28 Polymorphe formen eines gabaa-agonisten

Country Status (34)

Country Link
US (2) US7262300B2 (https=)
EP (2) EP1713813B1 (https=)
JP (1) JP4917440B2 (https=)
KR (1) KR101210361B1 (https=)
CN (1) CN1914212B (https=)
AR (1) AR047511A1 (https=)
AT (1) ATE414088T1 (https=)
AU (1) AU2005209473B2 (https=)
BR (1) BRPI0506858A (https=)
CA (1) CA2554536C (https=)
CO (1) CO5700743A2 (https=)
CY (1) CY1108647T1 (https=)
DE (1) DE602005010975D1 (https=)
DK (1) DK1713813T3 (https=)
DO (1) DOP2005000013A (https=)
EA (1) EA009413B1 (https=)
EC (1) ECSP066735A (https=)
ES (1) ES2314613T3 (https=)
GB (2) GB0402118D0 (https=)
HR (1) HRP20080614T3 (https=)
IL (1) IL176863A0 (https=)
MA (1) MA28364A1 (https=)
MX (1) MXPA06008595A (https=)
MY (1) MY139525A (https=)
NO (1) NO20063843L (https=)
NZ (1) NZ548191A (https=)
PE (1) PE20050769A1 (https=)
PL (1) PL1713813T3 (https=)
PT (1) PT1713813E (https=)
SI (1) SI1713813T1 (https=)
TW (1) TWI345972B (https=)
UA (1) UA87487C2 (https=)
WO (1) WO2005073237A2 (https=)
ZA (1) ZA200605307B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
WO2006083682A2 (en) * 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
ES2524994T3 (es) 2005-09-28 2014-12-16 Auris Medical Ag Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
EP2790686B1 (en) 2011-12-12 2021-03-10 Zilentin Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3880201A4 (en) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder
EP4051272A4 (en) 2019-12-18 2023-01-04 Ovid Therapeutics Inc. GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1P36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4315934A (en) 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
EP1220658A1 (en) 1999-09-28 2002-07-10 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
CA2447417C (en) 2001-05-18 2011-10-04 Lonza Ag Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
CN1511026A (zh) 2001-05-21 2004-07-07 H��¡�±������޹�˾ 加波沙朵颗粒制剂
CN100491366C (zh) * 2002-09-03 2009-05-27 华晶基因技术有限公司 汉黄芩素用作治疗焦虑症的药物的用途
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2008504306A (ja) 2004-06-29 2008-02-14 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛、線維筋痛症または慢性関節リウマチの治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
WO2006102093A1 (en) 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol

Also Published As

Publication number Publication date
CO5700743A2 (es) 2006-11-30
HK1096547A1 (en) 2007-06-01
CA2554536A1 (en) 2005-08-11
AR047511A1 (es) 2006-01-25
EP2042505A1 (en) 2009-04-01
BRPI0506858A (pt) 2007-05-29
NZ548191A (en) 2010-04-30
WO2005073237A2 (en) 2005-08-11
US8236958B2 (en) 2012-08-07
PE20050769A1 (es) 2005-10-04
ECSP066735A (es) 2006-10-31
EP1713813B1 (en) 2008-11-12
TWI345972B (en) 2011-08-01
US20070259912A1 (en) 2007-11-08
DK1713813T3 (da) 2009-02-16
DOP2005000013A (es) 2005-08-15
WO2005073237A3 (en) 2005-10-20
EP1713813A2 (en) 2006-10-25
KR101210361B1 (ko) 2012-12-10
ES2314613T3 (es) 2009-03-16
GB2410434A (en) 2005-08-03
MY139525A (en) 2009-10-30
CN1914212A (zh) 2007-02-14
TW200534856A (en) 2005-11-01
GB0501847D0 (en) 2005-03-09
NO20063843L (no) 2006-08-29
EA200601404A1 (ru) 2006-12-29
PT1713813E (pt) 2008-12-26
AU2005209473A1 (en) 2005-08-11
ZA200605307B (en) 2007-11-28
JP4917440B2 (ja) 2012-04-18
SI1713813T1 (sl) 2009-02-28
CN1914212B (zh) 2010-10-06
US20050171142A1 (en) 2005-08-04
PL1713813T3 (pl) 2009-04-30
CY1108647T1 (el) 2014-04-09
HRP20080614T3 (en) 2009-01-31
KR20070007070A (ko) 2007-01-12
MXPA06008595A (es) 2006-08-28
ATE414088T1 (de) 2008-11-15
MA28364A1 (fr) 2006-12-01
CA2554536C (en) 2012-09-18
UA87487C2 (ru) 2009-07-27
EA009413B1 (ru) 2007-12-28
JP2007519697A (ja) 2007-07-19
IL176863A0 (en) 2006-10-31
AU2005209473B2 (en) 2010-03-04
US7262300B2 (en) 2007-08-28
GB0402118D0 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
DE602005010975D1 (de) Polymorphe formen eines gabaa-agonisten
EP1890546A4 (en) COMPOSITION FOR INCREASING THE BIOLOGICAL AVAILABILITY OF CURCUMIN
FI20065404L (fi) Prosessi perusöljyn valmistamiseksi
DE602007000192D1 (de) Gelenkstruktur eines roboters
DE602007003661D1 (de) Plattformflosse eines Gebläses
DK2489662T3 (da) Mellemprodukter af en ny fremgangsmåde til fremstillingen af 5-benzyliden-2-alkylimino-3-phenylthiazolidin-4-on derivater
DE602006018355D1 (de) Transdermale verabreichung eines meptazinolsalzes
EP2099611A4 (en) CONFIGURATION OF MANUFACTURED PRODUCT
DE602007006708D1 (de) Handgriff-Schalteinrichtung eines Fahrzeugs
DE602006003003D1 (de) Abgassystem eines Motorrads
IL184395A0 (en) Novel salt form of a dopamine agonist
DE602006017539D1 (de) Buchsenprofilstruktur eines synchronisators
DE112006003845A5 (de) Vorrichtung zum Abtrennen von Raumbereichen eines Raums
BRPI0718853A2 (pt) Método de produzir um derivado de 2-alquil-3-aminotiofeno
EP1848420A4 (en) POLYMORPH SHAPES OF A GABAA AGONIST
DE602005017539D1 (de) Verifikation eines Bitstromes
FI20050736A0 (fi) Reaaliaikaisen palvelun laatu
DE602006016728D1 (de) Innenteil eines festplattenlaufwerks
FI20050577A0 (fi) Menetelmä adamantaanijohdannaisten valmistamiseksi
FR2896995B1 (fr) Raquette de paddleball
EP1962026A4 (en) INDOOR UNIT OF AN AIR-CONDITIONING SYSTEM
DE602006008015D1 (de) Feste salzformen eines pyrrolsubstituierten 2-indolinons
DE602006015610D1 (de) Pedalanordnung eines Übungsgerätes
FR2883581B1 (fr) Abri a structure de profiles
DK1999128T3 (da) Tetomilast-polymorf

Legal Events

Date Code Title Description
8364 No opposition during term of opposition